GSK159797
- Generic Name
- GSK159797
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- LGY1VQ9622
- Background
GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
- Indication
Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT00358488
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00354666
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath